
Lirafugratinib + LITESPARK011
OncoPharm
00:00
Lirafugratinib Targets FGFR2 Cholangiocarcinoma
John Bazar explains lirafugratinib’s approval for FGFR2-altered advanced cholangiocarcinoma and compares its selectivity with other FGFR inhibitors.
Play episode from 00:30
Transcript


